2型糖尿病患者的empagliflozin和动脉硬:一个真实世界的病例控制研究
Francesco Tassone1, Cinzia Ferreri2, Arianna Rossi3
1Diabetes Division, Ospedale Maggiore di Chieri, Italy.
Endocrine, metabolic & immune disorders drug targets
|February 20, 2025
概括
像empagliflozin这样的-葡萄糖共运输体-2 (SGLT2) 抑制剂可显著降低2型糖尿病患者的动脉硬性. 这种治疗还可以改善体重,BMI和功能标志物.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- -葡萄糖共运输体-2 (SGLT2) 抑制剂在2型糖尿病 (T2DM) 中已知具有心血管和的益处.
- 动脉硬是糖尿病患者心血管风险的关键指标.
研究的目的:
- 评估empagliflozin在降低T2DM患者动脉硬性的疗效.
- 评估empagliflozin对其他心血管和脏参数的影响.
主要方法:
- 一项病例对照研究,涉及16名T2DM患者接受了empagliflozin治疗,以及16名未服用SGLT2抑制剂的对照.
- 脉冲波速度 (PWV) 和其他动脉硬度参数在基线和三个月后被测量.
- 此外,还评估了HbA1c,体重,BMI,eGFR和尿液中白蛋白与肌素的比率.
主要成果:
- 与对照组相比,empagliflozin显著降低了HbA1c,体重,BMI和PWV.
- 动脉硬度 (PWV) 在empagliflozin组显著改善 (P = 0.001).
- 尿中白蛋白与肌素比率显著改善 (p = 0.049),而EGFR保持不变.
结论:
- 中期的empagliflozin治疗显著降低了T2DM患者的动脉硬.
- 恩帕格利弗洛辛可能会改善内皮功能,正如阿尔伯与肌素比率的改善所表明的那样.
- 这些发现突显了SGLT2抑制剂在管理T2DM心血管风险方面的潜力.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
573
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
573
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
144
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
144
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
457
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
457